|
|
||||||||
Department of Physiology and Biophysics and Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson, Mississippi 39216 - 4505
| |
ABSTRACT |
|---|
|
|
|---|
Vascular resistance and
arterial pressure are reduced during normal pregnancy, but dangerously
elevated during pregnancy-induced hypertension (PIH), and changes in
nitric oxide (NO) synthesis have been hypothesized as one potential
cause. In support of this hypothesis, chronic inhibition of NO
synthesis in pregnant rats has been shown to cause significant
increases in renal vascular resistance and hypertension; however, the
cellular mechanisms involved are unclear. We tested the hypothesis that
the pregnancy-associated changes in renal vascular resistance reflect
changes in contractility and intracellular Ca2+
concentration ([Ca2+]i) of renal
arterial smooth muscle. Smooth muscle cells were isolated from
renal interlobular arteries of virgin and pregnant Sprague-Dawley rats
untreated or treated with the NO synthase inhibitor
nitro-L-arginine methyl ester (L-NAME; 4 mg · kg
1 · day
1 for 5 days), then loaded with fura 2. In cells of virgin rats incubated in
Hanks' solution (1 mM Ca2+), the basal
[Ca2+]i was 86 ± 6 nM. Phenylephrine
(Phe, 10
5 M) caused a transient increase in
[Ca2+]i to 417 ± 11 nM and maintained
an increase to 183 ± 8 nM and 32 ± 3% cell contraction.
Membrane depolarization by 51 mM KCl, which stimulates Ca2+
entry from the extracellular space, caused maintained increase in
[Ca2+]i to 292 ± 12 nM and 31 ± 2% contraction. The maintained Phe- and KCl-induced
[Ca2+]i and contractions were reduced in
pregnant rats but significantly enhanced in pregnant rats treated with
L-NAME. Phe- and KCl-induced contraction and
[Ca2+]i were not significantly different
between untreated and L-NAME-treated virgin rats or between
untreated and L-NAME + L-arginine treated pregnant rats. In Ca2+-free Hanks', application of Phe or
caffeine (10 mM), to stimulate Ca2+ release from the
intracellular stores, caused a transient increase in
[Ca2+]i and a small cell contraction that
were not significantly different among the different groups. Thus renal
interlobular smooth muscle of normal pregnant rats exhibits reduction
in [Ca2+]i signaling that involves
Ca2+ entry from the extracellular space but not
Ca2+ release from the intracellular stores. The reduced
renal smooth muscle cell contraction and
[Ca2+]i in pregnant rats may explain the
decreased renal vascular resistance associated with normal pregnancy,
whereas the enhanced cell contraction and
[Ca2+]i during inhibition of NO synthesis in
pregnant rats may, in part, explain the increased renal vascular
resistance associated with PIH.
vascular resistance; hypertension; calcium; contraction
| |
INTRODUCTION |
|---|
|
|
|---|
NORMAL PREGNANCY IS OFTEN associated with increases in plasma volume and cardiac output and decreases in peripheral vascular resistance and mean arterial pressure (10, 16, 19, 23, 56). In addition to the pregnancy-associated changes in the systemic hemodynamics, specific regional changes in the renal circulation have been reported, including significant increases in renal plasma flow and glomerular filtration rate and reduction in renal vascular resistance (2, 10, 11, 17, 62). The pregnancy-associated changes in volume homeostasis, systemic hemodynamics, and regional renal blood flow may represent, to a certain extent, consecutive adjustments to a primary decrease in vascular tone (18). An increase in nitric oxide (NO) production by many cell types, including vascular endothelial cells, during normal pregnancy (5, 12, 14, 39, 53) has been suggested to bring about decreases in vascular tone, vascular resistance, and arterial pressure by direct vasodilatory actions and by blunting the vascular responsiveness to circulating vasoconstrictor agonists (41, 44, 53). This is supported by reports that the expression and specific actions of NO synthase (NOS) in several tissues, particularly those of the kidney, are elevated during late gestation (1, 12, 52, 60) and that the plasma level, metabolic production, and urinary excretion of cyclic cGMP, a second messenger of NO and a cellular mediator of vascular smooth muscle relaxation, are increased during pregnancy (13).
In ~5-10% of all pregnancies, women develop a condition called preeclampsia. Preeclampsia is characterized by severe edema, proteinuria, increased vascular resistance, and pregnancy-induced hypertension (PIH) (35, 36, 48, 54, 66). Although the exact mechanisms of PIH have not been clearly identified, abnormal reduction in NO synthesis during late pregnancy has been hypothesized as one potential cause (3, 6, 9, 21, 28). In support of this hypothesis, we and others have shown that chronic inhibition of NOS in rats during mid- to late gestation is associated with many of the pathological changes observed in women with PIH including significant increases in renal vascular resistance and arterial pressure (5, 28, 40, 47, 63). However, the intermediary vascular and cellular mechanisms involved in the increased renal vascular resistance observed during NOS inhibition in late pregnancy are not fully understood.
We have previously reported that the vascular reactivity of large-conduit arteries, such as the thoracic aorta, is decreased in pregnant rats but significantly enhanced in pregnant rats chronically treated with NOS inhibitors, and alteration of one or more of the signaling mechanisms of vascular smooth muscle contraction has been suggested as one possible cause (15, 29). It is generally accepted that vascular smooth muscle contraction is triggered by increases in intracellular free Ca2+ concentration ([Ca2+]i) due to Ca2+ release from the intracellular stores and Ca2+ entry from the extracellular space (32). In addition, several protein kinases and phosphatases, such as myosin light chain kinase, protein kinase C, Rho-kinase, and mitogen-activated protein kinase, have been suggested to contribute to smooth muscle contraction (25, 27, 55). Although previous studies from our laboratory and others' have suggested pregnancy-associated changes in the vascular Ca2+-mobilization mechanisms (15, 49), these studies were performed on large-conduit arteries, such as the thoracic aorta, and therefore, the findings of these studies may not apply to the physiologically more relevant small resistance arteries particularly those of the kidney. Also, in these previous studies, radioactive 45Ca2+ was used to provide a rather crude estimate of the net aortic uptake of all lumped forms of Ca2+, both bound and free, and therefore did not provide accurate measurements of the pregnancy-associated changes in the more pertinent activator [Ca2+]i in vascular smooth muscle. In effect, to our knowledge, no information is available on the pregnancy-associated changes in [Ca2+]i in vascular smooth muscle, in general, or in the smooth muscle of the physiologically more relevant small resistance arteries of the kidney, in particular. Furthermore, because pregnancy may be associated with multiple vascular changes in various types of vascular cells, studying the pregnancy-associated changes in the Ca2+-mobilization mechanisms of vascular smooth muscle contraction in a multicellular vascular preparation such as the aorta could be difficult, making it necessary to measure [Ca2+]i in single vascular smooth muscle cells. Although [Ca2+]i has previously been measured in single preglomerular arterial smooth muscle cells of male rats (51), no information is available on the pregnancy-associated changes in [Ca2+]i in single renal interlobular smooth muscle cells of female rats.
The purpose of the present study was to test the hypothesis that the reduction of renal vascular resistance during normal pregnancy and its increase during NOS inhibition in late pregnancy are associated with changes in contractility and [Ca2+]i of renal arterial smooth muscle cells. The specific aims were 1) to determine whether normal pregnancy in rats is associated with reduction in contractility and [Ca2+]i of single renal interlobular arterial smooth muscle cells, 2) to determine whether chronic reduction in NO synthesis during late pregnancy is associated with increases in contractility and [Ca2+]i of renal arterial smooth muscle cells, and 3) to determine the source of the pregnancy-associated changes in [Ca2+]i of renal arterial smooth muscle cells, if any, and whether it is due to changes in the Ca2+-release mechanisms from the intracellular stores and/or the Ca2+-entry pathways from the extracellular space.
The resting cell length and basal [Ca2+]i and the changes in cell contraction and [Ca2+]i in response to smooth muscle activators with different mechanisms of action were measured in single smooth muscle cells freshly isolated from renal interlobular arteries of virgin and pregnant Sprague-Dawley rats untreated or treated with the NOS inhibitor nitro-L-arginine methyl ester (L-NAME), then loaded with the Ca2+ indicator fura 2.
| |
METHODS |
|---|
|
|
|---|
Animals. Female virgin (10-12 wk of age) and time-pregnant (day 12 of gestation) Sprague-Dawley rats were purchased from Harlan Sprague Dawley (Indianapolis, IN). The rats were housed individually in the animal facility and maintained on ad libitum standard rat chow on a 12:12-h light-dark cycle. Virgin rats were either untreated (n = 24) or treated with L-NAME (n = 24). Late-pregnant rats were studied at days 19-21 of gestation (n = 24). Other late-pregnant rats were treated with L-NAME (n = 24) or with L-NAME plus the NOS substrate L-arginine (n = 12). The average weight of virgin rats was 240 ± 5.8 g compared with 349 ± 2.9 g in late-pregnant rats. All procedures were performed in accordance with the guidelines of the Animal Care and Use Committee at the University of Mississippi Medical Center and the American Physiological Society.
Protocol for L-NAME treatment.
Pregnant and virgin rats in the untreated groups received drinking
water. Pregnant and virgin rats in the treated groups received L-NAME (Sigma, St. Louis, MO) at a dose of ~4
mg · kg
1 · day
1. This
relatively small dose of L-NAME has been shown to cause significant elevation of blood pressure in pregnant rats, whereas it
has a minimal effect in virgin rats (15, 29, 40).
L-NAME treatment of the pregnant rats began at day
15 of gestation and continued for 4-6 days before the rats
were killed and the tissues harvested at days 19-21 of
gestation. Because water intake in pregnant rats was approximately two
times that in virgin rats, the amount of L-NAME in the
drinking water was adjusted to maintain a daily dose of ~4
mg · kg
1 · day
1 in both
pregnant and virgin rats. Some of the L-NAME-treated pregnant rats simultaneously received L-arginine (Sigma)
in the drinking water at a dose of ~80
mg · kg
1 · day
1 for the
same period of time (4-6 days). L-Arginine did not
significantly affect the amount of drinking water in pregnant rats.
Therefore, the amount of L-NAME the animals ingested was
similar between pregnant rats treated with L-NAME and
pregnant rats treated with L-NAME plus
L-arginine. With the use of this protocol, the recorded systolic blood pressure on the day of the experiment, using an automated sphygmomanometer with a tail cuff device, was 118 ± 3 mmHg in virgin rats, 125 ± 6 mmHg in virgin rats treated with L-NAME, 113 ± 5 mmHg in late-pregnant rats, 172 ± 6 mmHg in late-pregnant rats treated with L-NAME, and
124 ± 3 mmHg in late-pregnant rats simultaneously treated with
L-NAME plus L-arginine.
Single cell isolation.
Rats were anesthetized by inhalation of isoflurane. The kidneys were
rapidly removed and placed in oxygenated Krebs solution. The main
branches of the right and left renal arteries were carefully dissected
under microscopic visualization down to the interlobular renal arteries
(
150 µm diameter). Single renal arterial smooth muscle cells were
freshly isolated using a gentle procedure, specifically avoiding
aspiration through a pipette or centrifugation as previously described
(31, 42). Interlobular renal arterial strips (50 mg) were
placed in a siliconized flask containing a tissue digestion mixture of
collagenase type II (236 U/mg protein activity, Worthington, Freehold,
NJ), elastase grade II (3.25 U/mg protein activity, Boehringer
Mannheim, Indianapolis, IN), and trypsin inhibitor type II-soybean
(10,000 U/ml, Sigma) in 7.5 ml of Ca2+- and
Mg2+-free Hanks' solution supplemented with 30% bovine
serum albumin (Sigma). The tissue was incubated three consecutive times
in the tissue digestion mixture to yield three batches of cells. For the first batch, the tissue was incubated with 5 mg collagenase, 4 mg
elastase, and 147 µl trypsin inhibitor for 60 min. For batches 2 and 3, the collagenase was reduced to 2.5 mg, the
trypsin inhibitor was reduced to 122 µl, and the incubation period
was reduced to 30 min. The tissue preparation was placed in a shaking
water bath at 34°C in an atmosphere of 95% O2 and 5%
CO2. At the end of each incubation period, the preparation
was rinsed with 12.5 ml Hanks' with albumin and poured over glass
coverslips placed in wells and cooled to 2°C. By using the
gravitational force, the cells were allowed to settle and adhere to the
glass coverslips. Ca2+ was gradually added back to the
preparation to avoid the "calcium paradox" (45).
Contractility studies.
Coverslips with the attached cells were mounted on a square-shaped
opening in the middle of Plexiglas holders using a vaseline seal to
prevent leakage of the incubation solution. The coverslip holders were
placed on the stage of an inverted Nikon (Diaphot-300) microscope, and
the cells were viewed using a Nikon 100× oil-immersion objective. The
cell-isolation procedure yielded smooth muscle cells of variable
lengths. Only viable, healthy, and spindle-shaped cells
40 µm in
length were selected in this study. Viable, healthy cells adhered to
the glass coverslips and appeared bright, with a halo along the
periphery, and without a visible nucleus when viewed with
phase-contrast optics. The viability of the smooth muscle cells was
confirmed by their consistent and significant contraction in response
to phenylephrine (Phe) and KCl. The cells were further characterized
and consistently showed significant immunofluorescence signal when
labeled with anti-smooth muscle myosin antibody. Cell images were
acquired using a PXL charge-coupled device camera
(Photometrics, Tucson, AZ) and displayed on a personal computer using
PMIS image analysis software (Photometrics). The number of pixels
corresponding to the cell length in the cell image was transformed into
micrometers using a calibration bar.
5 M), caffeine (10 mM), and
KCl (51 mM) were measured, and the magnitude of cell contraction was
expressed as [(Li
L)/Li] × 100, where Li is the initial cell length and L is the final cell length.
Measurement of [Ca2+]i. [Ca2+]i was measured in fura 2-loaded single renal arterial smooth muscle cells using the ratio method as previously described (30, 42, 61). The cells were incubated in the fura 2 loading solution for 30 min at 34°C. The loading solution was made of normal Hanks' solution supplemented with 1 µM of the cell permeant fura 2-acetoxymethyl ester (fura 2-AM; Molecular Probes, Eugene, OR) and 0.01% Pluronic F-127 (Sigma). The fura 2-loaded cells were washed twice and further incubated in normal Hanks' solution for at least 30 min to allow complete deesterification of the dye. Nonspecific intracellular esterases hydrolyze the fura 2-AM ester and liberate the Ca2+-sensitive indicator fura 2 (24). Due to the photosensitivity of the fura 2 molecule, precautionary measures were taken throughout the procedure to avoid extensive photobleaching.
The fura 2-loaded cells were viewed through a Nikon Fluor 100× oil-immersion objective (NA 1.3) on an inverted Nikon (Diaphot-300) microscope. The Ca2+ indicator was excited alternately at 340 ± 5 and 380 ± 6 nm using a filter wheel that alternates between the two filters at a frequency of 0.5 Hz. The emitted light was collected at 510 nm to a photomultiplier tube R928 (Ludl Electronic Products, Hawthorne, NY) through a pinhole aperture 1 µm in diameter positioned 1 µm from the plasma membrane and 1 µm from the nucleus. The fluorescent signal was digitized using a module (Mac 2000, Ludl) and analyzed on a personal computer using data-analysis software. The signal-to-noise ratio was improved by averaging eight consecutive fluorescent intensity readings collected by the photomultiplier tube. The fluorescent signal was background subtracted. Spectral shifts that result from binding of the Ca ion allow the fura 2 indicator to be used ratiometrically, making the measurement of [Ca2+]i less sensitive to changes in cell thickness or the extent of dye loading and photobleaching. The 340/380 fluorescence ratio (R) was calculated from the fluorescence intensity at 340 nm divided by that at 380 nm and transformed to the corresponding levels of [Ca2+]i as described by Grynkiewicz et al. (24): [Ca2+]i = Kd(Sf2/Sb2)[(R
Rmin)/(Rmax
R)], where
Rmin and Rmax represent the minimal and maximal
fluorescence ratios and were measured by adding fura 2-pentapotassium
salt (50 µM) into Ca2+-free (10 mM) and
Ca2+-replete (2 mM) EGTA solutions, respectively, using
Ca2+-EGTA buffers. Kd is the
dissociation constant of fura 2 for Ca2+.
Sf2/Sb2 is the ratio of the 380 signal in
Ca2+-free and Ca2+-replete solutions,
respectively. Because the basal and maintained agonist-stimulated
changes in [Ca2+]i showed significant
fluctuations, 10 consecutive measurements were averaged in each
individual cell.
The effects of Phe, caffeine, and membrane depolarization by high KCl
on [Ca2+]i were measured in cells of
different groups of rats. To further identify the mechanisms of
Phe-induced increases in [Ca2+]i, some cells
were treated with phentolamine to block
-adrenergic receptors,
neomycin and
1-(6-((17
-3-methoxestra-1,3,5(10)-trien-17-yl)amino)hexyl)- 1H-pyrole-2,5-dione
(U-73122) to inhibit phospholipase C, or NiCl2 and
diltiazem to block Ca2+ entry through plasmalemmal
Ca2+ channels.
Solutions. Krebs solution was used for dissecting the tissue and contained (in mM) 120 NaCl, 5.9 KCl, 25 NaHCO3, 1.2 NaH2PO4, 11.5 dextrose, 2.5 CaCl2, and 1.2 MgCl2 at pH 7.4. Hanks' solution was used for cell isolation and for performing the experiments and contained (in mM): 137 NaCl, 5.4 KCl, 0.44 KH2PO4, 0.42 Na2HPO4, 4.17 NaHCO3, 5.55 dextrose and 10 HEPES. The solution was bubbled for 30 min with a 95% O2-5% CO2 mixture, and the pH was adjusted to 7.4. For Ca2+- and Mg2+-containing Hanks', 1 mM CaCl2 and 1.2 mM MgCl2 were added. For Ca2+-free Hanks', CaCl2 was omitted and replaced with 2 mM EGTA.
Drugs and chemicals.
Stock solutions of Phe (10
1 M, Sigma) and phentolamine
(10
2 M, Sigma) were prepared in distilled water. Caffeine
(Sigma) was prepared as 10 mM in Ca2+-free (2 mM EGTA)
Hanks' solution. Neomycin sulfate and U-73122 were purchased from
Biomol (Plymouth Meeting, PA). Diltiazem was purchased from Calbiochem
(La Jolla, CA). All other chemicals were of reagent grade or better.
Statistical analysis. The data are presented as the means ± SE. The raw data were analyzed using ANOVA with multiple classification criteria [pregnancy (pregnant vs. virgin) and L-NAME treatment (treated vs. untreated)] followed by Bonferroni's posttest to compare selected groups or Dunnett's posttest to compare all groups with the control virgin group. Differences were considered statistically significant if P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Resting cell length and Phe-induced contraction in renal arterial
smooth muscle cells.
The cell-isolation procedure produced cells of variable lengths. Only
spindle-shaped cells
40 µm in length were selected in this study
(Fig. 1A, top). In
resting cells of virgin rats, the average cell length was 57.5 ± 1.2 µm (n = 25; Fig. 1B). The resting cell
length was longer in pregnant rats (64.5 ± 1.5 µm, n = 25) but shorter in pregnant rats treated with
L-NAME (46.5 ± 1.3 µm, n = 20)
compared with virgin rats (Fig. 1, A and B). The
resting cell length was not significantly different between virgin rats
untreated or treated with L-NAME or between pregnant rats
untreated or treated with L-NAME + L-arginine (Fig. 1, A and B).
|
5 M)
caused contraction of the cells that reached a plateau after ~5 min
(Fig. 1A, bottom). The average Phe-induced cell
contraction after 5 min of stimulation was compared in the different
groups of rats. In cells of virgin rats, Phe (10
5 M)
caused 32 ± 3% (n = 25) cell contraction (Fig.
1C). The Phe-stimulated cell contraction was reduced in
pregnant rats (21 ± 1.5%, n = 25) but
significantly enhanced in pregnant rats treated with L-NAME (46 ± 2%, n = 20) compared with virgin rats
(Fig. 1C). The Phe-induced cell contraction was not
significantly different between virgin rats untreated or treated with
L-NAME or between pregnant rats untreated or treated with
L-NAME + L-arginine (Fig. 1C).
Basal and Phe-induced
[Ca2+]i in normal Hanks'
solution (1 mM Ca2+).
The basal and Phe-stimulated [Ca2+]i were
measured in cells of the different groups of rats. To avoid the
fluctuations in the basal [Ca2+]i
measurements (Fig. 2), 10 consecutive
measurements were averaged in each individual cell. In resting cells of
virgin rats, the average basal [Ca2+]i was
86 ± 6 nM (n = 25). Phe caused a transient
initial peak in [Ca2+]i followed by a
steady-state increase that was maintained for at least 5 min (Fig. 2).
Both the initial and maintained increase in
[Ca2+]i were abolished in cells treated with
the
-adrenergic blocker phentolamine (1 µM; Fig. 2A).
Also, the Phe-induced increases in [Ca2+]i
were significantly inhibited in cells treated with the phospholipase C
inhibitor neomycin (0.5 mM; Fig. 2B) or U-73122 (10 µM;
data not shown).
|
|
|
5 M) caused an initial peak
in [Ca2+]i to 417 ± 11 nM
(n = 25; Fig. 4, A and C) and a
maintained increase in [Ca2+]i to 183 ± 8 nM (n = 25; Fig. 4, A and D).
The Phe-induced initial peak [Ca2+]i was not
significantly different among the different groups of rats (Fig.
4C), suggesting no difference in Ca2+ release
from the intracellular stores. In contrast, the Phe-induced and
maintained [Ca2+]i (Fig. 4D) was
significantly reduced in pregnant rats (149 ± 8 nM,
n = 25) but significantly enhanced in pregnant rats
treated with L-NAME (234 ± 11 nM, n = 20) compared with virgin rats, suggesting pregnancy-associated
differences in Ca2+ entry from the extracellular space. On
the other hand, the Phe-induced, maintained
[Ca2+]i was not significantly different
between virgin rats untreated or treated with L-NAME or
between pregnant rats untreated or treated with L-NAME + L-arginine (Fig. 4D).
Cell contraction and
[Ca2+]i in
Ca2+-free medium.
To further investigate the role of the intracellular Ca2+
release mechanisms, the Phe response in Ca2+-free (2 mM
EGTA) Hanks' solution was measured. In cells of virgin rats incubated
in Ca2+-free (2 mM EGTA) Hanks' for 1 min, the basal
[Ca2+]i was reduced to 33 ± 2 (n = 32), which was not significantly different from
that in cells isolated from the other groups of virgin and
pregnant rats. Also, in cells of virgin rats, Phe (10
5
M) caused 10 ± 1% (n = 16) cell
contraction (Fig. 5A) and a
transient increase in [Ca2+]i to 329 ± 15 nM (n = 16), which were not significantly different from the respective measurements in the other groups of rats (Fig. 5,
B and C). Similarly, in Ca2+-free (2 mM EGTA) Hanks' solution, caffeine (10 mM) caused 8 ± 1.5%
(n = 16) cell contraction (Fig.
6A) and a transient increase in [Ca2+]i to 434 ± 14 (n = 16) in cells of virgin rats, which were not significantly different from the respective measurements in the other
groups of virgin and pregnant rats (Fig. 6, B and
C).
|
|
Effect of membrane depolarization by high KCl.
To further investigate whether the observed pregnancy-associated
changes in cell contraction and [Ca2+]i
reflect changes in Ca2+ entry from the extracellular space,
the response to high KCl solution was measured. Membrane depolarization
by high KCl is known to stimulate Ca2+ entry through
voltage-gated Ca2+ channels (32, 33). In cells
of virgin rats, KCl (51 mM) caused cell contraction that reached a
plateau after ~5 min. KCl also caused an increase in
[Ca2+]i that was maintained for at least 5 min (Fig. 7, A and
B). The KCl-induced increase in
[Ca2+]i was completely abolished by the
nonselective Ca2+ entry blocker NiCl2 (1 mM;
Fig. 7A) or the Ca2+-channel blocker diltiazem
(1 µM; Fig. 7B), suggesting that it is due to
Ca2+ entry from the extracellular space.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The present study showed that the resting cell length of
resistance renal arterial smooth muscle cells was longer in pregnant rats than in virgin rats, suggesting reduction in basal smooth muscle
tone in resistance renal arteries during pregnancy. These data are
consistent with other reports that the intrinsic basal tone of isolated
resistance mesenteric arteries and renal interlobar arteries is reduced
during late pregnancy in rats (22, 38). We also found that
the contraction of renal arterial smooth muscle cells in response to
-adrenergic stimulation by Phe was reduced in pregnant rats compared
with virgin rats. Although the observed decrease in renal arterial
smooth muscle cell contraction to Phe in pregnant rats can be explained
by a decrease in the sensitivity to Phe at the
-adrenergic receptor
level, it could also be due to inhibition of signaling mechanisms
downstream from receptor activation.
The interaction of Phe with its receptor is believed to cause
activation of phospholipase C and to increase the hydrolysis of
phosphatidlylinositol 4,5-bisphosphate into inositol
1,4,5-trisphosphate (IP3) and diacylglycerol
(7). IP3 stimulates Ca2+ release
from intracellular stores (57), and diacylglycerol stimulates protein kinase C (27, 46). In addition, Phe may enhance Ca2+ entry through plasma membrane Ca2+
channels (32). We found that the Phe-induced contraction
and [Ca2+]i in renal arterial smooth muscle
cells were completely abolished by the
-adrenergic blocker
phentolamine, suggesting that the Phe-induced contraction and
[Ca2+]i are mediated via
-adrenergic
receptors. Also, the significant inhibition of Phe-induced contraction
and [Ca2+]i by the phospholipase C
inhibitors neomycin and U-73122 provides evidence that the Phe
responses involve activation of PLC, which, in turn, increases the
turnover of plasma membrane phospholipids. The observation that the
initial Phe-induced Ca2+ transient was still observed in
Ca2+-free solution and in cells treated with the
Ca2+-channel blockers NiCl2 and diltiazem
provides evidence that the initial peak
[Ca2+]i is mainly due to Ca2+
release from the intracellular stores. On the other hand, the complete
inhibition of the maintained Phe-induced increase in [Ca2+]i in Ca2+-free solution or
in cells treated with the Ca2+-channel blockers
NiCl2 and diltiazaem provides evidence that the maintained
increase in [Ca2+]i involves Ca2+
entry from the extracellular space.
We found that the Phe-induced cell contraction and transient increase in [Ca2+]i in Ca2+-free solution, which are often used as measures of IP3-releasable intracellular Ca2+ stores (32, 33), were not significantly different in pregnant rats compared with virgin rats, suggesting that the reduced smooth muscle cell contraction and [Ca2+]i observed in pregnant rats are not due to changes in Ca2+ uptake to or Ca2+ release from the IP3-releasable intracellular Ca2+ stores. Also, the caffeine-induced contraction and transient increase in [Ca2+]i in Ca2+-free solution, which are often used as measures of the Ca2+-induced Ca2+-release mechanism from the intracellular Ca2+ stores (34), were not significantly different in pregnant rats compared with virgin rats, providing further evidence that the reduced smooth muscle cell contraction and [Ca2+]i observed in pregnant rats are less likely due to changes in Ca2+ uptake to or Ca2+ release from the intracellular stores.
We found that the Phe-induced, maintained [Ca2+]i in Ca2+-containing medium was reduced in pregnant rats compared with virgin rats, suggesting that a Ca2+-entry pathway may be reduced in renal arterial smooth muscle during pregnancy. To investigate the possible Ca2+-entry pathways involved, we compared the Phe response with that induced by KCl. Membrane depolarization by high KCl is known to stimulate Ca2+ entry through voltage-gated Ca2+ channels (32, 33). The present study showed that the KCl-induced cell contraction and [Ca2+]i were completely inhibited by the Ca2+-channel blockers NiCl2 and diltiazem, supporting the contention that the KCl responses involve Ca2+ entry from the extracellular space. Also, the KCl-induced cell contraction and [Ca2+]i were reduced in normal pregnant rats, providing evidence that Ca2+ entry from the extracellular space, possibly through voltage-gated Ca2+ channels, and into renal arterial smooth muscle is reduced during pregnancy. The cause of the reduced Ca2+ entry from the extracellular space is unclear at the present time but could be related to the possibility that either the Ca2+ permeability or the number of voltage-gated Ca2+ channels is reduced during pregnancy and should represent an important area for future investigations. However, the present results cannot exclude the possibility that other types of Ca2+ channels may also be involved in the observed decrease in Phe-induced cell contraction and [Ca2+]i during pregnancy. These Ca2+ channels have been described in several types of smooth muscle and have been termed receptor-operated Ca2+ channels (32).
Although a clear relationship between the changes in systemic hemodynamics and regional renal blood flow observed during late pregnancy and the renal arterial smooth muscle cell contraction and [Ca2+]i is difficult to discern at the present time, such a relationship is conceivable. It has been suggested that an increase in endogenous NO production during late pregnancy causes a decrease in vascular reactivity (39, 53), perhaps through increased formation of cGMP in vascular smooth muscle (12, 13). Other studies have shown that cGMP reduces [Ca2+]i by decreasing Ca2+ entry from the extracellular space through voltage-gated Ca2+ channels (37, 50, 58). On the basis of these premises, one would predict that blocking NO production during late pregnancy would bring the renal arterial smooth muscle cell contraction and [Ca2+]i back to the level observed in virgin rats. However, we observed that the Phe- and KCl-induced cell contraction and [Ca2+]i in pregnant rats treated with L-NAME were significantly greater than those in virgin rats and virgin rats treated with L-NAME. These results suggest that treatment of pregnant rats with L-NAME not only inhibits NO synthesis but may also increase the synthesis of, or sensitivity to, other vasoactive compounds that would increase the Phe- and KCl-induced cell contraction and [Ca2+]i. It has been hypothesized that abnormal reduction in uteroplacental blood flow during late pregnancy could trigger the release of certain cytokines from the placenta that, in turn, may alter the endothelial cell function leading to reduction in the synthesis of vasodilators such as NO or prostacyclin or, more importantly, increased production of vasoconstrictor factors such as endothelin or thromboxanes (4, 5, 40, 47). In support of this hypothesis, preliminary studies from our laboratory have shown that chronic NO-synthesis inhibition during pregnancy in rats is associated with an increase in the urinary excretion of thromboxanes (47). Also, it has been reported that long-term inhibition of NO synthesis during mid- to late gestation in rats is associated with increased blood pressure and elevated plasma levels of endothelin-1 (20). Thus evidence for an increase in the release of thromboxanes and endothelin has been observed during chronic inhibition of NO synthesis in pregnant rats. Thromboxanes and endothelin have also been shown to increase vascular reactivity by increasing Ca2+ entry through Ca2+ channels in vascular smooth muscle (8, 26, 43, 59, 64, 65), specifically in preglomerular renal arterial smooth muscle (51). However, the question remains whether the vascular reactivity to thromboxanes and endothelin is enhanced in isolated vascular smooth muscle preparations of pregnant rats chronically treated with NOS inhibitors compared with untreated control pregnant rats and should represent important areas for future investigations.
We found that the Phe- and caffeine-induced [Ca2+]i transient and cell contraction in Ca2+-free solution were not significantly changed in pregnant rats treated with L-NAME compared with pregnant rats, virgin rats, or virgin rats treated with L-NAME, suggesting that the enhanced cell contraction in pregnant rats treated with L-NAME is not due to changes in Ca2+ uptake to or Ca2+ release from the intracellular stores. On the other hand, the observed increase in the Phe-induced, maintained [Ca2+]i and contraction in pregnant rats treated with L-NAME suggest increased Ca2+ entry from the extracellular space through one or more type of excitable Ca2+ channel. The present results suggest that the enhanced cell contraction and [Ca2+]i in pregnant rats treated with L-NAME may involve stimulation of Ca2+ entry through voltage-gated Ca2+ channels, because the cell contraction and [Ca2+]i in response to KCl, a known activator of voltage-gated Ca2+ channels, were enhanced in pregnant rats treated with L-NAME. The enhanced Ca2+ entry could well be related to an increase in the permeability of the individual Ca2+ channel or to an increase in the number of voltage-gated Ca2+ channels. However, the present results cannot rule out the possibility that other types of excitable Ca2+ channels, such as the receptor-operated Ca2+ channels, may also be involved. Also, the enhanced Phe-induced cell contraction could be due to activation of other contractile mechanisms in addition to Ca2+ entry. For example, Phe may activate protein kinase C through increased formation of diacylglycerol (27, 31, 46).
Finally, the present study showed that, compared with the L-NAME-treated pregnant rats, in pregnant rats simultaneously treated with L-NAME + L-arginine, the Phe- and KCl-induced cell contraction and [Ca2+]i were significantly reduced to levels not significantly different from those observed in the untreated pregnant rats, lending support to the contention that the enhanced responses observed in the L-NAME-treated pregnant rats are possibly due to inhibition of the L-arginine-NO pathway.
In conclusion, the present results provide evidence that in renal arterial smooth muscle, cell contraction and [Ca2+]i are reduced during pregnancy but significantly enhanced during chronic inhibition of NO synthesis in pregnant rats. The pregnancy-associated changes in renal arterial smooth muscle cell contraction and [Ca2+]i involve Ca2+ entry from the extracellular space but not Ca2+ release from the intracellular stores. The reduced renal arterial smooth muscle cell contraction and [Ca2+]i in control pregnant rats may explain the decreased renal vascular resistance associated with normal pregnancy. The enhanced renal arterial smooth muscle cell contraction and [Ca2+]i during inhibition of NO synthesis in late-pregnant rats may, in part, explain the increased renal vascular resistance associated with PIH.
Perspectives
Understanding the changes in the cellular mechanisms of vascular smooth muscle contraction in animal models of PIH should help us to better understand the pathophysiological basis of preeclampsia in pregnant women. Abnormal reduction in uteroplacental blood flow during late pregnancy has been suggested as an initiating event that triggers a cascade of events leading to increased vascular resistance and hypertension. Several intermediary events have been suggested including the release of cytokines from the placenta, which may, in turn, alter endothelial cell function leading to reduction in the synthesis of vasodilators such as NO or prostacyclin or increased production of vasoconstrictor factors such as endothelin or thromboxanes. The present results in pregnant rats chronically treated with NOS inhibitor provide evidence that reduction of NO production during late pregnancy is associated with increased contractility and [Ca2+]i in renal interlobular arterial smooth muscle cells and may, therefore, represent one of the intermediary mechanisms of the increased renal vascular resistance associated with PIH. Other possible intermediary mechanisms, such as reduction in prostacyclin synthesis or increased production of endothelin and thromboxanes, are less clear and should be investigated in future studies.| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by National Heart, Lung, and Blood Institute Grants HL-51971 and HL-33849 to J. P. Granger and HL-52696 to R. A. Khalil and a grant-in-aid from the American Heart Association, Mississippi affiliate.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: R. A. Khalil, Dept. of Physiology and Biophysics, Univ. of Mississippi Medical Center, 2500 North State St., Jackson, MS 39216-4505 (E-mail: rkhalil{at}physiology.umsmed.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 30 May 2000; accepted in final form 7 September 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Alexander, BT,
Miller MT,
Kassab S,
Novak J,
Reckelhoff JF,
Kruckeberg WC,
and
Granger JP.
Differential expression of renal nitric oxide synthase isoforms during pregnancy in rats.
Hypertension
33:
435-439,
1999
2.
Baylis, C.
The determinants of renal hemodynamics in pregnancy.
Am J Kidney Dis
9:
260-264,
1987[ISI][Medline].
3.
Baylis, C,
Beinder E,
Suto T,
and
August P.
Recent insights into the roles of nitric oxide and renin-angiotensin in the pathophysiology of preeclamptic pregnancy.
Semin Nephrol
18:
208-230,
1998[ISI][Medline].
4.
Baylis, C,
and
Engels K.
Adverse interactions between pregnancy and a new model of systemic hypertension produced by chronic blockade of endothelial derived relaxing factor (EDRF) in the rat.
Clin Exp Hypertens
B11:
117-129,
1992.
5.
Baylis, C,
Suto T,
and
Conrad K.
Importance of nitric oxide in control of systemic and renal hemodynamics during normal pregnancy: studies in the rat and implications for preeclampsia.
Hypertens Pregnancy
15:
147-169,
1996.
6.
Beinder, E,
Mohaupt MG,
Schlembach D,
Fischer T,
Sterzel RB,
Lang N,
and
Baylis C.
Nitric oxide synthase activity and Doppler parameters in the fetoplacental and uteroplacental circulation in preeclampsia.
Hypertens Pregnancy
18:
115-127,
1999[ISI][Medline].
7.
Berridge, MJ,
and
Irvine R.
Inositol trisphosphate, a novel second messenger in cellular signal transduction.
Nature
312:
315-321,
1984[Medline].
8.
Bkaily, G,
Naik R,
D'Orleans-Juste P,
Wang S,
and
Fong CN.
Endothelin-1 activates the R-type Ca2+ channel in vascular smooth-muscle cells.
J Cardiovasc Pharmacol
26, Suppl3:
S303-S306,
1995.
9.
Buhimschi, IA,
Saade GR,
Chwalisz K,
and
Garfield RE.
The nitric oxide pathway in pre-eclampsia: pathophysiological implications.
Hum Reprod
4:
25-42,
1998.
10.
Chapman, AB,
Abraham WT,
Zamudio S,
Coffin C,
Merouani A,
Young D,
Johnson A,
Osorio F,
Goldberg C,
Moore LG,
Dahms T,
and
Schrier RW.
Temporal relationships between hormonal and hemodynamic changes in early human pregnancy.
Kidney Int
54:
2056-2063,
1998[ISI][Medline].
11.
Conrad, KP.
Possible mechanisms for changes in renal hemodynamics during pregnancy: studies from animal models.
Am J Kidney Dis
9:
253-259,
1987[ISI][Medline].
12.
Conrad, KP,
Joffe GM,
Kruszyna H,
Kruszyna R,
Rochelle LG,
Smith RP,
Chavez JE,
and
Mosher MD.
Identification of increased nitric oxide biosynthesis during pregnancy in rats.
FASEB J
7:
566-571,
1993[Abstract].
13.
Conrad, KP,
and
Vernier KA.
Plasma levels, urinary excretion and metabolic production of cGMP during gestation in rats.
Am J Physiol Regulatory Integrative Comp Physiol
257:
R847-R853,
1989
14.
Conrad, KP,
and
Whittemore SL.
NG-monomethyl-L-arginine and nitroarginine potentiate pressor responsiveness of vasoconstrictors in conscious rats.
Am J Physiol Regulatory Integrative Comp Physiol
262:
R1137-R1144,
1992
15.
Crews, JK,
Novak J,
Granger JP,
and
Khalil RA.
Stimulated mechanisms of Ca2+ entry into vascular smooth muscle during NO synthesis inhibition in pregnant rats.
Am J Physiol Regulatory Integrative Comp Physiol
276:
R530-R538,
1999
16.
Davidge, ST,
and
McLaughlin MK.
Endogenous modulation of the blunted adrenergic responses in resistance-sized mesenteric arteries from the pregnant rat.
Am J Obstet Gynecol
167:
1691-1697,
1992[ISI][Medline].
17.
Davison, JM,
and
Dunlop W.
Renal hemodynamics and tubular function in normal human pregnancy.
Kidney Int
18:
152-161,
1980[ISI][Medline].
18.
Duvekot, JJ,
Cheriex EC,
Pieters FA,
Menheere PP,
and
Peeters LH.
Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone.
Am J Obstet Gynecol
169:
1382-1392,
1993[ISI][Medline].
19.
Duvekot, JJ,
and
Peeters LL.
Renal hemodynamics and volume homeostasis in pregnancy.
Obstet Gynecol Surv
49:
830-839,
1994[Medline].
20.
Edwards, DL,
Arora CP,
Bui DT,
and
Castro LC.
Long-term nitric oxide blockade in the pregnant rat: effects on blood pressure and plasma levels of endothelin-1.
Am J Obstet Gynecol
175:
484-488,
1996[ISI][Medline].
21.
Friedman, SA,
Lubarsky SL,
Ahokas RA,
Nova A,
and
Sibai BM.
Pre-eclampsia and related disorders: clinical aspects and relevance of endothelin and nitric oxide.
Clin Perinatol
2:
343-355,
1995.
22.
Gandley, RE,
Griggs KC,
Conrad KP,
and
McLaughlin MK.
Intrinsic tone and passive mechanics of isolated renal arteries from virgin and late-pregnant rats.
Am J Physiol Regulatory Integrative Comp Physiol
273:
R22-R27,
1997
23.
Groenedijk, R,
Trimbos JB,
and
Walenburg HC.
Hemodynamic measurements in preeclampsia: preliminary observation.
Am J Obstet Gynecol
150:
232-236,
1984[ISI][Medline].
24.
Grynkiewicz, G,
Poenie M,
and
Tsien RY.
A new generation of Ca2+ indicators with greatly improved fluorescence properties.
J Biol Chem
260:
3440-3450,
1985
25.
Horowitz, A,
Menice CB,
Laporte R,
and
Morgan KG.
Mechanisms of smooth muscle contraction.
Physiol Rev
76:
967-1003,
1996
26.
Inoue, Y,
Oike M,
Nakao K,
Kitamura K,
and
Kuriyama H.
Endothelin augments unitary calcium channel currents on the smooth muscle cell membrane of guinea-pig portal vein.
J Physiol (Lond)
423:
171-191,
1990
27.
Kanashiro, CA,
and
Khalil RA.
Signal transduction by protein kinase C in mammalian cells.
Clin Exp Pharmacol Physiol
25:
974-985,
1998[ISI][Medline].
28.
Kassab, S,
Miller MT,
Hester R,
Novak J,
and
Granger JP.
Systemic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats.
Hypertension
31:
315-320,
1998
29.
Khalil, RA,
Crews JK,
Novak J,
Kassab S,
and
Granger JP.
Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats.
Hypertension
31:
1065-1069,
1998
30.
Khalil, RA,
Lajoie C,
and
Morgan KG.
In situ determination of [Ca2+]i threshold for translocation of the
-protein kinase C isoform.
Am J Physiol Cell Physiol
266:
C1544-C1551,
1994
31.
Khalil, RA,
and
Morgan KG.
Phenylephrine-induced translocation of protein kinase C and shortening of two types of vascular cells of the ferret.
J Physiol (Lond)
455:
585-599,
1992
32.
Khalil, RA,
and
van Breemen C.
Mechanisms of calcium mobilization and homeostasis in vascular smooth muscle and their relevance to hypertension.
In: Hypertension: Pathophysiology, Diagnosis, and Management, edited by Laraagh JH,
and Brenner BM.. New York: Raven, 1995, p. 523-540.
33.
Khalil, RA,
and
van Breemen C.
Sustained contraction of vascular smooth muscle: calcium influx or C-kinase activation?
J Pharmacol Exp Ther
244:
537-542,
1988
34.
Leijten, PA,
and
van Breemen C.
The effects of caffeine on the noradrenaline-sensitive calcium store in rabbit aorta.
J Physiol (Lond)
357:
327-339,
1984
35.
Lindheimer, MD,
and
Katz AI.
Hypertension in pregnancy.
N Engl J Med
313:
675-680,
1985[ISI][Medline].
36.
Lindheimer, MD,
and
Katz AI.
Preeclampsia: pathophysiology, diagnosis, and management.
Annu Rev Med
40:
233-250,
1989[ISI][Medline].
37.
Liu, H,
Xiong Z,
and
Sperelakis N.
Cyclic nucleotides regulate the activity of L-type calcium channels in smooth muscle cells from rat portal vein.
J Mol Cell Cardiol
29:
1411-1421,
1997[ISI][Medline].
38.
Meyer, MC,
Brayden JE,
and
McLaughlin MK.
Characteristics of vascular smooth muscle in the maternal resistance circulation during pregnancy in the rat.
Am J Obstet Gynecol
169:
1510-1516,
1993[ISI][Medline].
39.
Molnar, M,
and
Hertelendy F.
NG-nitro L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy induced refractoriness to vasopressor agents.
Am J Obstet Gynecol
166:
1560-1567,
1992[ISI][Medline].
40.
Molnar, M,
Suto T,
Toth T,
and
Hertelendy F.
Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation.
Am J Obstet Gynecol
170:
1458-1466,
1994[ISI][Medline].
41.
Moncada, S,
Palmer RMJ,
and
Higgs EA.
Nitric oxide: physiology, pathophysiology and pharmacology.
Pharmacol Rev
43:
109-142,
1991[ISI][Medline].
42.
Murphy, JG,
and
Khalil RA.
Gender-specific reduction in contractility and [Ca2+]i in vascular smooth muscle cells of female rat.
Am J Physiol Cell Physiol
278:
C834-C844,
2000
43.
Nakajima, T,
Hazama H,
Hamada E,
Wu SN,
Igarashi K,
Yamashita T,
Seyama Y,
Omata M,
and
Kurachi K.
Endothelin-1 and vasopressin activate Ca2+-permeable non-selective cation channels in aortic smooth muscle cells: mechanism of receptor-mediated Ca2+ influx.
J Mol Cell Cardiol
28:
707-722,
1996[ISI][Medline].
44.
Nathan, L,
Cuevas J,
and
Chaudhuri G.
The role of nitric oxide in the altered vascular reactivity of pregnancy in the rat.
Br J Pharmacol
114:
955-960,
1995[ISI][Medline].
45.
Nayler, WG,
Perry SE,
Elz JS,
and
Daly MJ.
Calcium, sodium, and the calcium paradox.
Circ Res
55:
227-237,
1984
46.
Nishizuka, Y.
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.
Science
258:
607-614,
1992
47.
Novak, J,
Cockrell K,
Kassab S,
Reckelhoff JF,
and
Granger JP.
Chronic nitric oxide synthesis inhibition during pregnancy increases thromboxane excretion in rats (Abstract).
FASEB J
11:
A78,
1997.
48.
Probst, BD.
Hypertensive disorders of pregnancy.
Emerg Med Clin North Am
12:
73-89,
1994[Medline].
49.
Roy, B,
Sicotte B,
Brochu M,
and
St-Louis J.
Modulation of calcium mobilization in aortic rings of pregnant rats: contribution of extracellular calcium and of voltage-operated calcium channels.
Biol Reprod
60:
979-988,
1999
50.
Ruiz-Velasco, V,
Zhong J,
Hume JR,
and
Keef KD.
Modulation of Ca2+ channels by cyclic nucleotide cross activation of opposing protein kinases in rabbit portal vein.
Circ Res
82:
557-565,
1998
51.
Schroeder, AC,
Imig JD,
LeBlanc EA,
Pham BT,
Pollock DM,
and
Inscho EW.
Endothelin-mediated calcium signaling in preglomerular smooth muscle cells.
Hypertension
35:
280-286,
2000
52.
Singh, R,
Pervin S,
Rogers NE,
Ignarro LJ,
and
Chaudhuri G.
Evidence for the presence of an unusual nitric oxide- and citrulline-producing enzyme in rat kidney.
Biochem Biophys Res Commun
232:
672-677,
1997[ISI][Medline].
53.
Sladek, SM,
Magness RR,
and
Conrad KP.
Nitric oxide and pregnancy.
Am J Physiol Regulatory Integrative Comp Physiol
272:
R441-R463,
1997
54.
Smith, MA.
Preeclampsia.
Prim Care
20:
655-664,
1993[ISI][Medline].
55.
Somlyo, AP,
Wu X,
Walker LA,
and
Somlyo AV.
Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases.
Rev Physiol Biochem Pharmacol
134:
201-234,
1999[Medline].
56.
Sowers, JR,
Zemel MB,
Walsh MF,
Standley PR,
Zemel PC,
Bronsteen RA,
Kraniak J,
and
Sokol RJ.
Effects of normal pregnancy on cellular cation metabolism and peripheral vascular resistance.
Am J Hypertens
3:
16-22,
1990[ISI][Medline].
57.
Suematsu, E,
Hirata M,
Hashimoto T,
and
Kuriyama H.
Inositol 1,4,5-trisphosphate releases Ca2+ from intracellular storage sites in skinned single cells of porcine coronary artery.
Biochem Biophys Res Commun
120:
481-485,
1984[ISI][Medline]